Patients who are candidates for autologous or allogeneic hematopoietic stem cell transplantation

Patients who were refractory to initial standard treatment

Patients who have a history of bendamustine administration and are intolerant to bendamustine

Patients with central nervous system (CNS) involvement of lymphoma or with a history of CNS involvement of lymphoma

Patients diagnosed with DLBCL transformed from low-grade B-cell non-Hodgkin's lymphoma (NHL)

\<Only for dose-expansion stage\>

\- Patients who have a history of rituximab administration and are intolerant to rituximab

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL